Home › Compound Library › Immune & Anti-Aging › Low-Dose IL-2 (Aldesleukin)
Immune & Anti-Aging Research Moderate Evidence

Low-Dose IL-2 (Aldesleukin)

Recombinant interleukin-2 at ultra-low doses studied for regulatory T-cell (Treg) expansion in autoimmune disease and immune aging. Distinct from high-dose IL-2 cancer immunotherapy — entirely different mechanism and safety profile at ultra-low doses.

IL-2regulatory T-cellTregautoimmuneimmune toleranceultra-low doseimmunotherapy
Half-life
~85 minutes half-life; ultra-low dose regimens: 3 days on/2 weeks off in trials
SKUs Available
1
Evidence Level
Moderate Evidence
Mechanism of Action

IL-2 receptor signaling preferentially activates Tregs at ultra-low doses (Treg IL-2R has higher sensitivity than effector T-cells). Expands and activates Foxp3+ regulatory T-cells which suppress autoreactive immune responses. Potential to restore immune tolerance in autoimmunity and reverse age-related immune dysregulation.

Published Research Ranges & Study Context

Studies have administered: 0.33–3 million IU/day (ultra-low vs 600,000 IU/kg for cancer) in Treg expansion trials; subcutaneous

Important Research Framing These are ranges reported in published scientific studies. They are provided for educational context only and do not constitute dosing recommendations. Individual study parameters vary by design, population, and research objectives. This information is not medical advice.
Primary Research Findings

TRANSREG trial (Klatzmann group): 0.5–1M IU/day expanded Tregs 20% without T effector expansion in type 1 diabetes. Hepatitis C vasculitis trial: clinical remission in majority. Multiple autoimmune trials ongoing. Age-related immune rejuvenation potential documented in aging models.

Moderate Evidence Phase 1/2 human trials available
Side Effects Observed in Research

At ultra-low doses: injection site reactions, mild flu-like symptoms — contrasts sharply with high-dose IL-2 toxicity profile; organ dose-dependent

Available Configurations (SKU Reference)
IL2-1
Compounds Studied in Combination

These compounds have been examined together in research literature. Combination use is not endorsed or recommended — this information is provided for research context only.

Want a Complete Research Monograph?

Our AI can generate a 2,000+ word deep-dive on Low-Dose IL-2 (Aldesleukin) — including full clinical trial summaries, pharmacokinetics, and research frontiers.

Generate Deep Dive in Research Chat
Research Education Only: This compound profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions. Regulatory status varies by jurisdiction.